Alex Nivorozhkin

Alex Nivorozhkin

Directeur Technique/Scientifique/R&D chez CYBIN INC.
66 ans
Health Technology
Health Services
Consumer Services

Profil

Dr. Alex Nivorozhkin is a Chief Scientific Officer at Cybin, Inc., a Chief Executive Officer & Director at Adelia Therapeutics, Inc., a Chief Operating Officer at Amorsa Therapeutics, Inc. and a Member at International Cannabinoid Research Society.
He is on the Board of Directors at Adelia Therapeutics, Inc. Dr. Nivorozhkin was previously employed as a Member by Boston BioCom LLC, a Senior Program Manager by Center For Integration of Medicine & Innovative Technology, a Head-Medicinal Chemistry by EPIX Pharmaceuticals, Inc., a Head-Medicinal Chemistry by Inotek Pharmaceuticals Corp., a Co-Founding Member by Neo-Advent Technologies LLC, and a Program Manager by The General Hospital Corp.
He received his doctorate degree from Rostov State University.

Postes actifs de Alex Nivorozhkin

SociétésPosteDébut
CYBIN INC. Directeur Technique/Scientifique/R&D 01/12/2020
Fondateur 01/01/2020
Directeur des opérations -
Corporate Officer/Principal -

Anciens postes connus de Alex Nivorozhkin

SociétésPosteFin
Center For Integration of Medicine & Innovative Technology
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Neo-Advent Technologies LLC
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Alex Nivorozhkin

Formation de Alex Nivorozhkin

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

6

Relations au 1er degré

11

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées11

Health Technology

Health Technology

Health Services

Health Technology

Center For Integration of Medicine & Innovative Technology

Consumer Services

Commercial Services

Health Technology

Health Technology

Health Technology

Neo-Advent Technologies LLC

  1. Bourse
  2. Insiders
  3. Alex Nivorozhkin
DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT